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1 Introduction 
1.1 The continuing problem of HIV infection 
Back in 1984, when AIDS was first shown to be caused by the human 
immunodeficiency virus (HIV) , the world was skeptical that any 
successful treatment would ever be found. Since then, much has 
been discovered about preventing and slowing the infection process, 
and we now have at our disposal more weapons than were ever 
thought possible. However, a cure still eludes all research efforts 
made in the past 13 years. 
AIDS is fast becoming an epidemic in many parts of the 
world, with an estimated 30.6 million people infected globally -
20 million of whom reside in sub-Saharan Africa. Still, the large 
amount of infected individuals is miniscule in comparison to the 
high percentage of these people who don't even know that they are 
infected [1]. Just this past year, the U.N. Program on HIV / AIDS 
estimated that nine out of ten HIV infected people in Africa are 
unknowingly harboring the virus and are ignorantly contributing to 
the spread of AIDS. Clearly, HIV infection is still one of the major 
health concerns of our time and will remain a problem until a readily 
available vaccine is developed. 
Though the present situation of HIV infection looks grim for 
less industrialized countries such as those in Africa, the other side 
of the globe is experiencing new hope. Due to concentrated research 
and public awareness efforts, the United States has actually expe-
rienced a drop in the HIV infected population. The difference here 
lies in the availability of medical care, heightened awareness and ed-
ucational programs, and access to quick and accurate HIV-positive 
testing. The sooner these measures can be adopted by underde-
veloped countries, the closer we may be to totally eradicating this 
harmful virus. 
Thanks to research efforts made by scientists in 1996, many 
new anti-HIV drugs have been developed, and some are now avail-
able by prescription. These chemotherapies, although not a cure, 
help delay the onset of the many symptoms of AIDS and prolong 
the life of many HIV infected patients. One must be cautious in 
the scheduling of this treatment though, since a large variety of side 
effects exist for each chemotherapy. These side effects have caused 
physicians and medical scientists to be locked in a tug-of-war be-
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tween treating a patient with maximal chemotherapy and admin-
istering a mediocre treatment schedule to lessen the detrimental 
effects of the drugs. 
1.2 Infection Background 
HIV belongs to the well known retroviral family, Retroviridae, which 
consists of viruses having an unique form of RNA replication. This 
replication begins with reverse transcription of virion RNA into a 
single strand of cD N A and is catalyzed by the enzyme reverse tran-
scriptase. Synthesis of cDN A involves the concurrent digestion of 
the viral RNA with the RNAse portion of the reverse transcriptase. 
After the linear double stranded DNA is complete, it is subsequently 
circularized, integrated into the host chromosomal DNA, and then 
used for transcription of the mRNA (for viral protein translation) 
and the full-length genomic RNA (for the newly formed virions) [5]. 
The host cells which HIV infects are human lymphocytes 
known as helper T cells. The helper T cell plays an integral role 
in immune response, and without them the human body is severely 
handicapped in fighting disease. Many opportunistic conditions can 
result if the helper T cell count is low enough, including fungal infec-
tions, bacterial infections, and rare forms of cancer. The first step 
of infection involves the binding of a virion to a receptor molecule 
on the host cell surface. The receptor for HIV, CD4, is a transmem-
brane protein which normally plays an important role in signaling 
between the helper T cells and the antigen presenting cells which 
provide antibody n1ediated immunity. Even when a portion of the 
CD4 receptor is bound to other cell surface molecules, it retains the 
HIV receptor activity and the virus can enter the cell by recognizing 
the receptor with its own 'key' molecule, gp120 or surface protein 
(SU) [5]. Also, the presence of a specific 'fusion receptor' for HIV 
is being invoked to explain the lack of infection of mouse hybrids 
expressing the human CD4 protein. Clearly, there must be some 
other factor which allows viral entry. This second essential receptor 
is known as a chemokine receptor, an example of which is CXCR4 
[13] . 
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In brief, the replication cycle followed by HIV consists of the 
following steps [5]: 
1) Attachment of the virion to the specific receptor on the host 
cell surface. 
2) Penetration of the virion core into the cell. 
3) Reverse transcription to copy viral genome RNA into DNA 
which can be inserted into the host. 
4) Transportation of the DNA to the nucleus. 
5) Integration of the viral DNA into random sites in cell DNA to 
form the provirus. 
6) Synthesis of viral RNA by cellular RNA polymerase II using 
the integrated provirus as the template. 
7) Post-transcriptional processing of RNA to form genome and 
mRNAs. 
8) Virion protein synthesis (translation of viral mRNAs). 
9) Assembly and budding of new virions. 
10) Proteolytic processing of capsid proteins via the viral protease 
enzyme. 
Since the HIV life cycle is quite different from any other cell 
in the human body, many antiretroviral treatments are available 
which take advantage of its uniqueness. AZT, for example, is a 
drug which inhibits the viral enzyme reverse transcriptase. AZT 
and other types of retroviral chemotherapy are collectively referred 
to as anti-HIV therapies. This designation includes any treatment 
which specifically stops HIV from reproducing or infecting its pri-
mary target, the helper T cells. It is conceivable that any of the 
above steps may be inhibited by a certain treatment, but as of now 
there are three main catagories of drugs available. 
The three basic types of anti-HIV chemotherapy currently 
available by prescription or through experimental trials are nucle-
oside reverse transcriptase inhibitors, non-nucleoside reverse tran-
scriptase inhibitors, and protease inhibitors. All of these agents limit 
HIV infection for some amount of time, but since the virus is highly 
mutagenic it eventually develops resistance, and the treatment soon 
becomes useless. Many experts believe that using combination or 
'cocktail' chemotherapy - two or more drugs administered simulta-
neously - may help slow the development of resistance by HIV and 
also act more efficiently in inhibiting viral reproduction. 
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1.3 An optimal control of HIV infection 
The main thrust of this investigation is to suggest an optimal method 
of treating HIV infection given the known facts about the infection 
process. Many mathematical models already exist describing HIV 
infection, and we propose using one of these models to monitor the 
progression of HIV infection in a patient. Of the many chemothera-
pies available, an experimental chemokine derivative was first chosen 
to prevent the virus from entering a T cell (13]. Recently, combina-
tion therapy has been applied to our study with an additional viral 
protease inhibitor. 
While ant i-HIV chemotherapy has been used for some time, 
an optimal treatment schedule has been at best a rough approxima-
tion. Until a cure is found, the primary problem faced by physi-
cians today is one of balance. Their objective is to inhibit the 
virus as much as possible while simultaneously holding the side 
effects of treatment to a minimum. This must be done by an 
'optimal' chemotherapy schedule - one which both maximizes pa-
tient's uninfected T cells, and minimizes any harmful effects that 
the chemotherapy might incur. Through mathenlatical modeling 
and optimal control theory, we propose an optimal treatment strat-
egy to strike a balance between the two effects. 
Our analysis begins with a description of the mathematical 
model used and then compares this model with others adopted by 
medical researchers today. Optimal control theory will then be ap-
plied to the model, and methods for solving our problem will be 
explained. Once our problem is set up, numerical methods will then 
be used to generate the resultant optimal treatment schedule for 
an HIV infected patient. A discussion of the results and potential 
future applications will follow thereafter. 
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2 Mathematically Modeling HIV Infection 
In the recent past, many mathematical models for the treatment of 
HIV infection have been developed [9], [11], [14], and [15]. An over-
whelmingly similar aspect of these models is their use of first order 
ordinary differential equations (ODE's) describing the interaction 
between the viral particles and the T cells. In each model, the T 
cells are assumed to express the CD4 and CXCR4 protein receptors 
on their surface and any others found in the future to be central to 
HIV entry [13J. This just means that for the modeled helper T cells, 
all of the requirements for HIV entry are met, and each helper T cell 
has an equal probability of being infected. Also notice that any other 
cell expressing the receptor can also be infected by HIV. This is how 
HIV 'hides out' in areas of the brain protected from chemotherapies 
by the blood-brain barrier [18J. In the model which was used, we 
assumed that these secondary infection sites play such a small role 
in the infection process that they may be neglected. However, some 
models take these other sites into account, and we will go over an 
example of this later in the section. For now, the model which was 
used in our analysis will be presented and explained. 
2.1 Our Model 
In order to begin the optimal control procedure, it is necessary to 
obtain a model which describes the basic interaction between HIV 
and the immune system's T cells. In [14] and [16], a model is given 
which simulates the infected scenario. We utilize this model and rec-
ommend that the reader see these papers for a complete derivation 
and verification. A brief discussion is presented below. 
The model consists of four states, three of which are T cell 
categories and another represents the HIV virus. We let T(t) repre-
sent the concentration (number of T cells per mm3 ) of uninfected T 
cells at time t, and T*(t) and T**(t) are used to denote the concen-
trations of latently infected and actively infected T cells, respectively 
at time t. Latently infected T* cells are those in which HIV has in-
serted its genetic material, but as of yet no virus is being produced 
from the host cell. Actively infected T** cells, as the name implies, 
actively produce HIV virions since, unlike T* cells, the viral genetic 
information has been 'turned on.' The concentration of free infec-
tious virus at time t will be denoted by V(t) (viral particles which 
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are able to infect and have not already entered a cell). Time t is 
measured in days in all equations in the following analysis. 
Each of the four states is a function of time and represents 
a solution to a first order differential equation describing infection 
kinetics. The left hand side of each equation is the first derivative of 
the state with respect to time. Hence, this derivative term represents 
the rate of growth of each state (in concentration per time) or equiv-
alently, the slope of the state function at each time point. Therefore, 
the units on the right hand side of the equation must agree with the 
concentration per unit time dimensions, so each major term sepa-
rated must also have these units. For example, in equation (1) the 
second term -J-tTT is actually -J-tT(days)-lT(concentration of T 
cells). Notice that the cOlnbination of units yields the desired result 
of concentration per unit time. The system of equations describing 
HIV infection consists of the following first order ODE's: 
(1) 
(2) 
(3) 
(4) 
dT _ s ( T + T* + T** ) ([[ - rtV - J-tTT + rT 1 - Tmax - kl VT, 
d];* = kl VT - J-tTT* - k2T*, 
dT** - k T* - II. T** 
--a;:r- - 2 rb, 
~ = N J-tbT** - kl VT - J-tv V. 
• In (1), 1 ~ V is positive and represents the production of new 
T cells inversely affected by the amount of virus [3, 10]. The 
second term, -J-tTT, models the exponential decay of the T cell 
population, with a death rate of -J-tTT. Our third term is the 
logistic growth of the T cell population with saturation occuring 
at T max' In order to see this, notice that when the total T cell 
population reaches its maximum, i.e. when T+T*+T** = Tmaxl 
the entire term rT ( 1 - T + t:~ T") becomes zero and will 
therefore not contribute to the growth of T cells. 
The fourth and final term in equation (I), -kl VT, deals with 
the interaction between the viral particles. This term is anal-
ogous to a second order rate law in enzyme kinetics in that 
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it assumes that both the concentration of T cells, T, and the 
virion concentration, V, contribute to the formation of infected 
T cells by combining with a rate constant of k1 . Once a T cell 
is invaded by the virus, it then becomes a latently infected T* 
cell. - kl VT is thus a loss term for healthy T cells in equation 
(1), and kl VT is a gain term for T* in equation (2). 
• In the ODE (2), the first term kl VT is a growth term for the 
population of latently infected cells. Also, these cells have two 
separate removal rates. The first, -J-LT, is as before a natural 
death rate constant for those T cells not producing virus. The 
second death rate constant, -k2' actually represents a transfer 
rate for this population into the next state T** described by 
equation (3). 
• The ODE (3) models the actively infected T cell population. 
As stated before, latently infected cells become actively infected 
with a rate constant of k2 . The second term -J-LbT** in (3) is a 
death rate for the actively infected T cells due to the production 
of virus. 
• The free virus population is described by our final ODE of the 
system, equation (4). We assume that each actively infected 
cell produces N viral particles before it dies. Also, whenever 
a virion infects a healthy T cell,' the virion itself enters the 
cell and is removed from the free virus population. Thus, the 
term - kl VT is a loss term for the free viral population, V. 
Any interaction of the virus with previously infected T cells 
is neglected since these cells soon lose their CD4 protein after 
initial infection due to down regulation of transcription by viral 
gene products [5]. The last term, -J-Lv V, lumps together viral 
loss of infectivity and removal from the body into a common 
death rate for the virus. 
Analysis of the stability is given in [9] and [16]. This system 
was shown to have two steady states, an uninfected steady state and 
an endemically infected steady state. The uninfected steady state 
occurs when no virus is present, i.e T To, T* = 0, T** = 0, and 
V = 0. The second, endemically infected steady state, occurs with 
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each of the cell populations at positive values. This second type is 
analogous to a remission period during the infection process. During 
this period, symptoms seemingly disappear from the patient and the 
T cell population appears to remain constant. However, the body is 
constantly producing T cells, but at this stage there exists a balance 
between the body's efforts and the rate of infection by the virus. 
Remission is a very delicate stage in any type of infection, and any 
perturbance could wildly shift the equilibrium toward problematic 
infection. 
In fact, Perelson et al. [16] showed that if the parameter 
N was below a critical value, Ncritl the uninfected steady state is 
stable and the infected steady state is unstable. At N Ncrit, 
The stability is exchanged through a bifurcation and the infected 
state becomes locally stable. For N > Ncrit, other bifurcations in 
the eigenvalues can occur, and therefore global stability could not 
be shown. As an example, it was shown that stability can be lost 
for the infected steady state giving rise to stable limit cycles. This 
behavior is believed to occur only for parameter values lying outside 
of the possible ranges of biological feasibility. 
Notice that these equations are coupled and nonlinear. In 
order to solve the first ODE, ~I, we must also have information 
about V, T*, and T** at each time t. Since these other equations 
are described by ODE's, we must solve the entire system at each 
time step until we can proceed to the next. 
2.2 Other Models 
Many other models describing HIV infection exist, and without a 
brief summary of the modeling progress we would leave the reader 
believing that everything about the modeling of HIV infection has 
been said and done. This is hardly the case. The disease course is 
far too complicated a process for an easy analysis to be performed. 
With the available data and hypothesized mechanisms gaining more 
and more support, the interaction between the virus and humans 
has been approached in a variety of different ways. Among many 
modelers, there is some controversy over which model is the best. We 
will discuss a few of these attempts to give the reader a better flavor 
of the model development process. Our starting point is a general 
model of two ordinary differential equations, and an expansion on 
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this primary model will lead us to an inclusion of variable parameters 
and non-lymphatic infection sites. 
In [17], the dynamics of cell infection and virion production 
are represented by 
(5) dT* = kTV - 8T* dt ' 
(6) dft = N8T* - cV, 
where T* T* (t) and V = V (t) are the populations of 
infected target cells and roaming virus, respectively at time t. The 
rate of decay of infected cells is -8T*, and the infection rate is given 
by kTV where T is the total population of uninfected T cells and is 
assumed constant in the time of treatment, i.e., it does not depend 
on time. This is the main difference between this model and our 
four-ODE model which accounts for longer intervals of treatment 
by assuming T = T(t). 
In the second ODE, (6), N is the average number of virions 
escaping the infected cell before complete cell lysis and is measured 
per infected cell per day and per lifetime of an infected cell. In a 
short period of time, the system is assumed to be in a steady state 
with T*(t) = T* and V(t) = if as constant values. This model, (5) 
and (6) is then perturbed by a protease inhibitor which interrupts 
viral production by inhibiting correct viral protein processing. The 
effect of this treatment is that only noninfectious viral particles es-
cape from the host cell. The differential equations for the perturbed 
system are 
(7) 
(8) 
(9) 
dT* -dT = kT~ 8T*, 
dV1 -c~, dt 
d~rI = N8T* - cVNJ, 
where ~(t) and VN1(t) are the concentrations of infectious 
and noninfectious virions, respectively, at the time after chemother-
apy begins. Although this model describes the general flow of the 
disease progression during a shortened time period, it does not take 
into account a change in the daily turnover rates of virus and T cell 
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populations with time. Another model which attempts to do so is 
being developed presently by Kirschner and Webb [11]. 
Kirschner and Webb's version of a predator-prey (Lotka-
Volterra type) model consists of a two differential equations in the 
general form of the equations 
(10) dT* dT k(t)TV 8(t)T*, 
(11) dJi- = 6(t)T* - c(t)V, 
where the constant rate parameters have been replaced by 
disease-course, time-dependent parameters. The equations (10) and 
(11) are identical to equations (5) and (6) except for this assumption 
of time dependence, and because of this, equations (10) and (11) 
more effectively model the nonlinearities of disease dynamics. Over 
the long frame of time that is used to model the effects of treatment 
on T cell and viral population, this variable coefficient model should 
be a better model. However, the previous model, (5) and (6), may 
be needed when modeling faster processes occuring in short period 
treatment intervals. 
As a final case of HIV infection models, an example using 
secondary sources of infection is now presented. These secondary 
infection sites may be neurons of the central nervous system or pos-
sibly other immune system cells such as macrophages. This model, 
by Perelson et al. [15], includes macrophage cells, M(t), in addition 
to T cells, T(t). Both uninfected cell types serve as hosts to the 
virus, V(t). Also, actively infected T cells are represented by T*(t) 
while latently infected T cells are represented by L(t). Notice that 
this contrasts our designation of the two infected states (see pages 5 
and 6), but one can easily see that the two states are essentially the 
same as (T*) - Land (T**) - T* with our model's state values rep-
resented in parentheses. Perelson's new kinetic model is proposed 
as follows: 
(12) 
(13) 
(14) 
dJt* = kVT + aL - 8T*, 
dft = jkVT - JLLL, 
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(15) dV f: ([[ NuT* pM* cV. 
In this model, all variables T, T*, M*, L, and V are functions 
of time. The immune system's cytotoxic T cells or macrophages, 
M, become infected at a rate constant kM and enter the long-lived 
infected cell state, M*. These cells continuously produce virus at an 
average rate per cell, pM*, and are lost at a death rate of -/tMM*. 
Another assumption in this model is that when T cells are 
infected, actively infected T* cells are generated with a rate con-
stant k, and latently infected T cells harboring viral information in 
their genome (total DNA) are generated with a rate constant jk, 
smaller by a factor of j. The growth of the latently infected T cells 
is modeled by equation (13), and they have a death rate of -8L L 
and a rate -aL of transformation into actively infected T* cells. 
The combination of the two rates of removal corresponds to a com-
bination removal rate constant of -/tL = -a - 8L . In equation (12), 
T* are lost with a removal rate of -8 and produce a total of N viral 
particles in the course of their infected lifetime. In the last ODE 
(15), virions, V, are cleared at a rate -cV. 
This model, like ours, was used to obtain an optimal combi-
nation of chemotherapies. The cocktail treatment included a pro-
tease inhibitor and two reverse transcriptase inhibitors [15]. 
Clearly, there is not only one correct way to model the HIV 
infection process. Our model may account for longer treatment pe-
riods and different infective states of the T cells, but it does not 
model the activity of the virus in other regions of the body. In some 
cases, such as when the patient exhibits AIDS related dementia, a 
more flexible model should be used, eg., one that models neuronal 
infection in the brain. Due to different initial assumptions, each 
model may be justifiable in different situations. Our treatment sit-
uation may neglect the presence of other compartments in the body 
susceptible to HIV infection, but it does take into account the latent 
and active states of T cell infection and more thoroughly describes 
the interaction between virus and healthy T cell. 
Having a more complicated model does not necessarily mean 
having a better model. It is entirely up to the medical researcher 
to decide which variables he or she wishes to neglect in an optimal 
treatment schedule for a patient. Our model, equations (1 )-( 4), will 
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soon be modified with chemotherapy terms and will be used as struc-
tural support for the objective function we seek to maximize. One 
should keep in mind that the following procedures may be initiated 
for the other models stated above. Before commenting on the mod-
ifications made in our model to include dual chemotherapies, the 
theory behind optimal control will briefly be explained. For more 
information on the existence and application optimal control, please 
refer to [7] and [12]. 
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3 Optimal Control 
3.1 Introduction to Optimal Control Theory 
Optimal control theory is a method used to solve for an extremum 
value of an objective functional involving dynamic variables. This 
maximizing or minimizing process is accomplished by adjusting the 
control variable, u, until the maximum or minimum is achieved. 
The control which yields the extreme value is denoted by u* and is 
called an optimal control. This control variable, which in our case 
is a function of time, can be used in many modeling situations and 
could be a function of any controlable variable, i.e. if one could 
directly manipulate the number of viruses, the u could be V. 
If the mathematical model consists of PDE's (partial dif-
ferential equations), the control will exhibit its action on infinite 
dimensional systems. In our case however, we use a deterministic 
control of a finite dimensional system in time, and the states of 
infection are described by ODE's. The variables are divided into 
two classes: state variables and control variables, both of which are 
functions of time in our model. The movement of state variables of 
infection is governed by first order ODE's, and the control affects 
the behavior of the ODE's in some way. The maximum principle 
developed by L.S. Pontryagin in the late 1950's gives a method to 
find the optimal control [7]. 
3.2 Our Objective 
Our control, u(t), represents an effective chemotherapy dosage bounded 
between 0.0% and 100.0%, or u(t) E [0,1] where u ranges from no 
chemotherapy (0.0) to a maximum dosage (1.0). In this problem, the 
primary goal is to maximize the healthy T cell count of an HIV in-
fected patient, and the secondary aim is to minimize any side effects 
caused by the chemotherapy control. Thus, the problem is to find 
the optimal chemotherapy percentage, u( t), throughout the length 
of treatment to ~ t ~ t f. This optimal control should maximize 
our objective, i.e., it should maximize both the healthy T cell con-
centration, T(t), and the negative value representing side effects, 
which is denoted by _~Bu2(t). In the side effects term, the ~B 
represents a balancing (B) constant which relates the percentage of 
chemotherapy in a meaningful way to the healthy T cell concentra-
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tion. Both the T cell concentration and side effects of chemotherapy 
are included in the objective functional, J(u). By definition [12], a 
functional maps functions into numbers. In our case, the functional 
J ( u) is an integral over the treatment time. Therefore, a control 
u(t) is sought to maximize the objective functional J(u) in equation 
(16): 
(16) 
If we apply two different control chemotherapies Ul (t) and 
U2(t), the problem is very similar except that the functional J(UI, U2) 
will be maximized with respect to both controls. The new objective 
functional is stated in equation (17), and takes into account the side 
effects of combination chemotherapy: 
(17) 
One can easily imagine implementing many more controls by 
simply tacking on each one's side effects to our objective functional. 
In both equations (16) and (17), chemotherapy benefits a patient 
by increasing the healthy T cell population, T(t), which is described 
by ODE (1) in our system. There also exists a certain 'cost' on the 
patient for administering a chemotherapy, and this cost represents 
the potential for harmful side effects from each drug. These side 
effects are taken into account by the balancing constants Bi for 
the control chemotherapy Ui. Each balancing term balances the 
systemic cost of its respective chemotherapy to the benefit measured 
in healthy T cell concentration. 
Although a consensus on the apparent costliness of chemother-
apy does not yet exist, the solution of the maximum of J was pursued 
with an adjustable value for each B. Practicing physicians using this 
study should weigh the apparent side effects of each drug adminis-
tered to the patient and proceed according to the optimal treatment 
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schedule generated by the following analysis. The solutions and ef-
fects of two optimal chemotherapies will now be implemented in our 
model. 
3.3 The Modified Model 
The optimal control used in this problem represents the percentage 
of the effect a chemotherapy has on inhibiting the virus. As stated 
before, each control Ui(t) is bounded on the interval [0,1] where 
U 0 implies no chemotherapy and U = 1 indicates maximum 
chemotherapy. Our control class consists of measurable functions 
defined on a limited window of treatment time [to, tf]. This treat-
ment period is limited in order to lessen the effects of resistance or 
side effects on the immediate state of the model. Since HIV has an 
extremely high rate of mutation, a portion of the viral population 
may develop resistance to a chemotherapy treatment after some fi-
nite amount of time. This necessitates a finite interval of treatment 
since the ineffective drug can still exhibit side effects. 
Previous work has already been done with controls which de-
creased viral load by multiplying the parameter N in equation (4) 
by the chemotherapy control representing a reverse transcriptase 
inhibitor [9, 16]. In our model, a similar type of control was used 
as well as another which inhibited the interaction between virus 
and T cell. The objective function used was essentially equation 
(17). The first control Ul (t) represents an inhibitory drug used 
to block viral binding to the T cell. This control is analogous to 
a chemokine-like substance which competitively or irreversibly in-
hibits a secondary receptor on a T cell required for HIV entry, for 
example the chemokine receptor CXCR4 [13]. Since Ul (t) blocks 
binding, it is attached to the term kl VT in both equations (1) and 
(2), but not equation (4). By applying the control in the manner of 
(1- ul(t))kl VT, the virus to T cell interaction is multiplied by zero 
if our control is at its maximum dosage of Ul(t) = 1. If however, 
the chemotherapy is absent (Le. Ul(t) = 0), complete interaction at 
a rate kl will resume in the system. 
The second control used in the model is denoted by U2(t). 
This control represents a viral protease inhibitor or any other chem-
ical (such as AZT, ddC, etc) which decreases viral production from 
an actively infected host cell. As in the case of our first control, this 
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chemotherapy will be applied as (1 U2(t)). Instead of inhibiting 
virus to T cell interaction, U2 affects the amount (N) of correctly 
processed virus budding from a T** cell. This control is applied in 
equation (4) in our system of equations. 
After applying both controls to our model, the system of 
equations is altered as follows, with the control terms in bold type: 
(18) 
(19) 
(20) 
(21) 
¥t 1 ~ V - JlTT rT( 1 - T + E~ TOO) - (1 - ul(t))kJ VT, 
dT* ([t = (1 - Ul (t) )kl VT /LTT * - k2T*, 
dT** - k T* - II. T** dt - 2 f"'b, 
N ow that the model has been modified to include two dif-
ferent controls, the optimization process can begin. Our goal, as 
stated previously, is to characterize the optimal controls ui (t) and 
u;(t) satisfying the maximum of the objective functional (17). The 
existence of an optimal control may be found in Fleming and Rishel 
[6]. In this problem, the necessary concavity of J(ui, u;) holds, and 
therefore the required conditions of Pontryagin's Maximum Princi-
ple have been met. 
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4 Solving the Optimal Control Problem 
4.1 Setting up the Maximum Problem 
In order to set up this maximization problem, the system of ODE's 
(equations (18-21)) must first be attached to the objective functional 
(equation (17)). This is accomplished by using the Lagrangian func-
tion, equation (22), with penalty terms attached for the bounds on 
the controls. For our problem, the Lagrangian is the integrand of 
the objective functional J(Ul' U2), equation (17), coupled with the 
state ODE's by means of functions known as adjoints, each of which 
is denoted by Ai(t) corresponding to the ith state. The penalty 
terms are denoted by Wi(t) with Wi(t) 2 0 for i = 1,2,3,4, and dd~i 
denotes the right hand side of each ODE in our system, for states 
Si = T, T*, T**, V from equations (18-21). The Lagrangian, L, is: 
(22) L = {T(t) - ~BIUI(t) - ~B2U~(t) } 
dT dT* dT** dV 
+Al dI + A2---a:t + A3([t + A4 dt 
+Wl ( Ul (t)) + W2 (1 Ul (t)) + W3 ( U2 (t)) + W4 (1 U2 (t)) . 
Since our problem contains bounded controls 0 ::; Ul, U2 ::; 
1, we made use of penalty multipliers, Wi, representing functions 
of time. These Wi'S are used to attach our control constraints. 
The penalty multi pliers satisfy Wl ( Ul ( t)) = 0, W2 (1 - Ul (t) ) 0, 
W3(U2(t)) = 0, and w4(1 - U2(t)) = 0 on Ub U2 E (0,1), with the 
additional constraint Wi 2 0 for all i. The penalty terms act to keep 
each control bounded in the interval [0, 1]. By Pontryagin's Maxi-
mum Principle, the Lagrangian is maximized with respect to Ul, U2 
at ut, u2 when the Lagrangian is evaluated at the optimal states and 
adjoints. 
Since we will now be maximizing the Lagrangian function 
with respect to each u, we must choose controls which are bounded 
on [0, 1]. In order to see this, consider what would happen to the 
penalty terms if either U < O. This choice of a control would cause 
the terms Wl(Ul(t)) and W3(U2(t)) to become negative and pull the 
Lagrangian function down and way from the maximum. Therefore 
negative values of U would not be chosen as controls for a maximum 
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L value. The same idea holds whenever our control escapes its 
upper bound of 1, again causing the Lagrangian to decrease and not 
attain its absolute maximum. Clearly, the only values which can 
maximize L are those between 0 and 1. The penalty terms will soon 
be implemented in order to put bounds on the optimal solution in 
section 4.3. 
4.2 Adjoint Conditions 
In order to attach the system of ODE's onto the objective function, 
adjoint functions were used. Pontryagin's maximum principle gives 
the necessary conditions that the adjoint functions must satisfy. The 
differential equation satisfied by the ith adjoint function, derived in 
reference [7], is the following: 
where i = 1,2,3,4 and Si = T, T*, T**, V. 
The adjoints have the following boundary conditions at the final 
time of treatment, tr 
i = 1,2,3,4. 
As one can easily see, there are as many adjoints as there are 
state equations, and the adjoint .Ai corresponds to the ith state vari-
able. Now, another difficulty has been introduced into the problem. 
Not only must four more first order ODE's be solved, but these ad-
joint ODE's have final conditions as opposed to the initial conditions 
of the state ODE's. This creates a problem in the iterative solving 
program which will be explained later in the following paragraphs. 
The ODE's describing the rate of change of each adjoint with respect 
to time will now be presented. Differentiating the Lagrangian (22) 
with respect to each state variable by the ith generating condition 
above gives the following equations: 
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(23) ~ -1 + AI(!1T - r + r( 2T + l:-: T") + (1 - uI)k l V) 
-A2(1 - ul)kt V + A4kl V, 
(24) ~ Al ( f!;,x) + A2(!1T + k2) - Aak2, 
(25) ~ Al (f!;,x) + Aa!1b - A4(N!1b(1- U2)), 
(26) dA4 Al (1 - ul)k1T - A2(1 - ut)ktT + A4(ktT + Jlv). dt 
For the untreated case (no controls), these adjoints are not 
needed and the iterative algorithm Runge-Kutta [2] may be used to 
solve the system of four state equations forward in time. Once for-
mulas were obtained for the optimal controls (see next section), the 
solving program was implemented to find the solution values during 
the treatment of an HIV infected patient. In order to solve for our 
optimal controls, a method commonly used in Calculus (differenti-
ation with respect to each control) was generalized for finding the 
maximum value of the Lagrangian's curve where the first derivative 
equals zero. 
Each of the adjoint ODE's has a boundary condition of zero 
at the final time of treatment, t f. This creates a problem in develop-
ing an iterative solver. Not only must the first four coupled ODE's 
(18-21) be solved forward in time from initial conditions, but also 
the second system of adjoint ODE's (23-26) must be solved back-
ward in time from their final conditions. The program would be a 
lot easier to implement if the ODE's were uncoupled, i.e., if they 
did not depend on one another, because then a simple Runge-Kutta 
program could solve the state ODE's forward in time, and a sepa-
rate loop could walk the adjoint ODE's backward in time. However, 
these two systems of four ODE's present a unique problem in that 
they are coupled to each other, and therefore the two systems must 
be solved simultaneously. 
A unique program was developed specifically for this need, 
and it iteratively solves the ODE systems by first guessing values 
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for the adjoints at all time t E [to, t f). These guesses were then 
used to solve the state ODE system which, in turn, yielded values 
for each state T, T* 1 T**, and V at time t. These state values were 
then plugged into the adjoint system which was subsequently solved 
using the Runge-Kutta method of order four backward in time from 
tf· 
After each run through the algorithm, the convergence was 
tested by comparing the absolute error between each state value at 
run k and the previous state value at run k 1. If the difference 
between the two values was greater than a specified tolerance, E, 
the newly generated adjoints from run k were cycled through the 
initial loop in place of the adjoint guesses. If however, the error was 
less than the specified tolerance, the iterative solve was terminated 
and the state data at t E [to, t f] was collected and placed in a ma-
trix. This matrix was subsequently exported to MATLAB4.2c, and 
graphs of the various states and controls versus time were obtained. 
4.3 The Optimality Condition 
The Lagrangian is maximized with respect to both U1 and U2 sep-
arately in order to obtain the optimal value of ui and u2. At both 
of these control values, the maximum Lagrangian is obtained. The 
derivative of the Lagrangian with respect to both ui and u 2 is thus 
zero, since at the absolute maximum the slope of a function is zero. 
First, partially differentiating our L with respect to U1 yields: 
which can then be solved for our optimal ui, giving us: 
* _ (AI - A2)k1VT+W1 - W2 
u1 - E1 . 
Thus, from the conditions on our penalty multipliers, Wi 2:: 0, the 
following expression may be obtained: 
(27) uj = Min ( MaX(*l,O),l), 
(AI - A2)k1 VT 
B1 where *1 
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In order to obtain an expression for our second optimal control, U2, 
the same method will be followed. This second analysis will proceed 
step-by-step. As before, the derivative of L with respect to U2 is set 
equal to zero, giving us: 
which can then be solved for u2 as follows: 
In order to eliminate the unknown penalty functions, consider 
3 disjoint and exhaustive cases on the optimal control: 
• Case (i) On the set {t I 0 < u2(t) < I}, we may set W3(t) = 
W4(t) = 0, hence generating the optimal control, 
• Case (ii) On the set {t I u2(t) = I}, W3(t) = 0 and W4(t) 2: 0, 
therefore giving us: 
which implies 
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• Case (iii) On the set .{t I u;(t) = OJ, w3(t) ~ 0 and W4(t) = 0, 
which gives us the relation: 
u;(t) o = -A4N ftbT ** + W3 > -A4N ftbT ** B2 - B2 
From this expression, our solution for the third case is obtained: 
N ow the reader can more easily see how the condition for u; in 
equation (28) is generated: 
(28) 
>.. N T** 
where *2 = - 4 B~b 
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5 Discussion of ~esults and Conclusions 
5.1 The Results 
The analysis is now complete. The equations for each optimal con-
trol have been obtained and have been implemented into a program 
which iteratively solves both systems of equations. Equations de-
scribing the HIV infected scenario have been implen1ented with dual 
chemotherapy - one, a chemokine-like derivative that inhibits bind-
ing (un and the other being that of a viral protease inhibitor that 
inhibits correct protein processing of new virions (u2). Both of these 
optimal controls represent solution curves for an optimal treatment 
schedule. Through a computational algorithm including both for-
ward and backward Runge-Kutta, we were able to numerically solve 
the two systems of ODE's, the state system and the adjoint system. 
The figures on the following pages are presented for percep-
tion of the process of infection, the optimal treatment schedule, and 
the effects that the optimal controls have on an HIV positive pa-
tient. Although the model without controls has been verified, the 
effect of this optimal combination treatment has not yet been shown 
to mimic our data. However, the methods which were used to at-
tain the optimal chemotherapy schedule has been verified previously 
[2, 6, 7], and research suggests that these optimal treatment sched-
ules are the true solution for this problem. 
The following is a description of each of the figures, all of 
which were produced using MATLAB: 
• FIGURE 1: The optimal treatment schedule of ui(t), 
Bl = 50, interval 100 days: 
Figure 1 represents the optimal 100 day treatment schedule for 
the first chemotherapy, ui - a chemokine-like binding inhibitor 
with Bl 50. % chemotherapy is plotted on the y-axis, and 
the number of days is on the x-axis . 
• FIGURE 2: The optimal treatment schedule of u2(t), 
B2 = 400, interval 100 days: 
Figure 2 represents the optimal 100 day treatment schedule 
for the second chemotherapy, u2* - a protease inhibitor with 
B2 400. 
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• FIG1JRE 3: The optimal treatment schedule of both 
u;:(t) and u2(t), with Bl 50 and B2 = 400, 350, 250, and 
150: 
Figure 3 consists of four separate graphs, each containing so-
lution curves of Ul in a solid line and U2 in a dashed line. As 
we decrease the cost of U2 from 400 to 150, the length of time 
of maximal U2 treatment increases from about 27 days to 67 
days, while the Ul treatment decreases proportionally. 
• FIGURE 4: T cell behavior, with and without optimal 
combination treatment for two sequential intervals of 
100 days: 
The solid line represents healthy T cell behavior during HIV in-
fection, while the dashed line represents what would happen to 
the T cell population given optimal combination chemotherapy 
for two successive 100 day intervals starting at day 900. 
• FIGURE 5: HIV behavior, with and without optimal 
combination treatment for two sequential intervals of 
100 days: 
The solid line represents viral behavior during infection, while 
the dashed line indicates viral population changes under opti-
mal combination treatment for two successive 100 day intervals 
beginning at day 900. 
• PRINTOUT: 
This printout contains the Fortran program used to solve our 
optimal control problem. The data generated from the program 
was plotted using MATLAB. 
5.2 Future Analysis 
Although anti-HIV treatment does slow the progression of the dis-
ease in HIV infected patients, much uncertainty exists about how 
to best administer the drug during the treatment period. Through 
this analysis, an optimal treatment schedule is put forward, to max-
inlize a patient's healthy T cell count while also keeping track of 
potential side effects of each chemotherapy. When a new drug has 
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passed FDA guidelines and has been tested through clinical trials, 
the maximum percentage dosage can be obtained and side effects 
will be recorded. After relating the side effects to the balancing 
constant in the objective equation, J(Ul' U2, ... ), one can then solve 
for an optimal treatment schedule which can serve as a guideline for 
HIV infected patients to follow. 
The unique numerical algorithm developed to solve this prob-
lem will serve as a template for future applications in the medicinal 
treatment of HIV infection. With new combinations of chemothera-
pies being developed, one can imagine the usefulness of such a com-
puter program. Mathematical modeling of HIV infection and solu-
tions of optimal control may serve as a stepping stone between clin-
ical medical research trials and actual implementation of the drug 
regiment throughout the HIV infected population. Truly, mathe-
matics does have a place in the medical field today. 
Other interesting studies would make use of modifications 
to the structure of our model. For example, one could check the 
reliability of the parameters by setting each as a function of time and 
performing a sensitivity analysis on them. Most seem to have one 
or two significant digits, and therefore they could vary significantly, 
i.e. .02 could vary from .015 to .024. Checking the sensitivity by 
perturbing each parameter would be useful in verifying the stability 
of this model. 
Special thanks to Dr. Suzanne Lenhart, Dr. Renee Fister, 
Dr. Charles Collins, Dr. Raj Pal Soni, and Rick Moran, without 
whom none of this would have been possible. 
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IMPLICIT NONE 
REAL B,B2,H,ICX(4),FCY,KX(4,4) ,KY(4,4),X(4,lOOl) 
REAL XN(4,lOOl) ,Y(4,lOOl) ,YN(4,lOOl) ,T,T1,T2,V,Y1,Y2,Y3,Y4 
REAL U1(1001) ,U2(1001) ,EPSI,SUM,TI,TF,X1,X2,X3,X4,Zl,Z2,Z3,Z4 
INTEGER I,N,M,K,P,COUNTER,Z 
X1(T,T1,T2,V,U1)= 
!10/(1+V)-.02*T+.03*T*(1-(T+T1+T2)/1500)-2.4E-5*(1-U1)*V*T 
X2(T,T1,V,U1)=2.4E-5*(1-U1)*V*T-(.02+.003)*T1 
X3 (T1,T2) .003*T1-.24*T2 
X4(T,T2,V,U2)=(1-U2)*1200*.24*T2-2.4E-5*V*T-2.4*V 
.,c Watch out for the 2.4's above and below, some should be 2.4*10A 5 etc ... ! 
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WI' 
Zl(Y1,Y2,Y4,T,T1,T2,V,U1)= 
!-1+Y1*(.02 .03+.03*(2*T+T1+T2)/1500+ 
!2.4E-5*(1-U1)*V)-2.4E-5*V*(Y2*(1-U1)-Y4) 
Z2(Y1,Y2,Y3,T)=(Y1*.03*T)/1500+.023*Y2 .003*Y3 
Z3(Y1,Y3,Y4,U2)=Y1*(.03*T)/1500+.24*(Y3-(1-U2)*1200*Y4) 
Z4(Y1,Y2,Y4,T,V,U1)= 
!Y1*(10/«1+V)**2)+2.4E-5*T*(1-U1))-Y2*2.4E-5*(1-U1)*T+ 
!Y4*(2.4E-5*T+2.4) 
This 
COUNTER=O 
TI 0.0 
TF=lOO.O 
N=lOOO 
M=lOOl 
H=(TF-TI)/N 
FCY=O.O 
EPSI=.Ol 
Z=2 
B=.50E2 
B2=4.0E2 
ICX(1)=874.022 
ICX(3) 1.51225E-02 
ICX(2) 1.10754 
ICX(4) .566098 
XN(l,l)=ICX(l) 
XN(2,1)=ICX(2) 
XN(3,l)=ICX(3) 
XN(4,l) ICX(4) 
is the initial guess for the 4 adjoint eqns 
DO P=l,4 
DO I=l,M 
Y(P,I)=l.O 
END DO 
END DO 
The next step is the start of the MAjor ! ! 
MAybe use a GO TO statement at the end of the loops to the line directly below 
Y(l) is the initial condition, all the way to Y(lOl) which is Y at time 2 
The next loop is to find ICU (U(l))and all other U values 
DO I=l,M 
IF (2.4E-5*XN(4,I)*XN(l,I)*(Y(1,I)-Y(2,I))/B.GT.0.AND . 
!2.4E-5*XN(4,I)*XN(1,I)*(Y(l,I)-Y(2,I))/B.LT.1) THEN 
U1(I)=2.4E-5*XN(4,I)*XN(l,I)*(Y(1,I)-Y(2,I) )/B 
ELSE 
IF(2.4E-5*XN(4,I)*XN(1,I)*(Y(1/I)-Y(2,I) )/B.LE.O) THEN 
U1 (I) 0.0 
ELSE 
U1(I)=1.0 
END IF 
END IF 
IF (-Y(4,I)*1200*.24*XN(3,I)/B2.GT.O.AND. 
!-Y(4,I)*1200*.24*XN(3,I)/B2.LT.1) THEN 
U2(I)=-Y(4,I)*1200*.24*XN(3,I)/B2 
ELSE 
IF(-Y(4,I)*1200*.24*XN(3,I)/B2.LE.O) THEN 
U2(I)=O.O 
ELSE 
U2(I)=1.0 
END IF 
END IF 
IF (I.EQ.M) THEN 
GO TO 123 
ELSE 
END IF 
KX(1,1)=H*X1(XN(1,I) ,XN(2,I) ,XN(3,I) ,XN(4,I) ,U1(I)) 
KX(2,1)=H*X2(XN(1,I) ,XN(2,I) ,XN(4,I) ,U1(I)) 
KX(3,1)=H*X3(XN(2,I) ,XN(3,I)) 
KX(4,1)=H*X4(XN(1,I) ,XN(3,I) ,XN(4,I) ,U2(I)) 
KX(1,2)=H*X1(XN(1,I)+KX(1,1)/2,XN(2,I)+KX(2,1)/2,XN(3,I)+ 
!KX(3,1)/2,XN(4,I)+KX(4,1)/2, (U1(I+1)+U1(I))/2) 
KX(2,2)=H*X2(XN(1,I)+KX(1,1)/2,XN(2,I)+KX(2,1)/2,XN(4,I)+ 
! KX ( 4 , 1) 12, (U1 ( I + 1 ) + U1 (I) ) 12 ) 
KX(3,2)=H*X3(XN(2,I)+KX(2,1)/2,XN(3,I)+KX(3,1)/2) 
KX(4,2)=H*X4(XN(1,I)+KX(1,1)/2,XN(3,I)+KX(3,1)/2,XN(4,I)+ 
! KX (4 , 1) 12, (U2 ( I + 1) + U2 (I) ) 12) 
KX(l,3)=H*X1(XN(l,I)+KX(1,2)/2,XN(2,I)+KX(2,2)/2,XN(3,I)+ 
!KX(3,2)/2,XN(4,I)+KX(4,2)/2, (U1(I+1)+U1(I))/2) 
KX(2,3)=H*X2(XN(1,I)+KX(1,2)/2,XN(2,I)+KX(2,2)/2,XN(4,I)+ 
! KX ( 4 , 2 ) 12, (U 1 ( I + 1 ) + U1 ( I) ) 12 ) 
KX(3,3)=H*X3(XN(2,I)+KX(2,2)/2,XN(3,I)+KX(3,2)/2) 
KX(4,3)=H*X4(XN(1,I)+KX(1,2)/2,XN(3,I)+KX(3,2)/2,XN(4,I)+ 
! KX ( 4 , 2 ) 12, (U2 ( I + 1) + U2 (I) ) 12) 
KX(1,4)=H*X1(XN(1,I)+KX(1,3) ,XN(2,I)+KX(2,3) ,XN(3,I)+ 
!KX(3,3) ,XN(4,I)+KX(4,3) ,U1(I+1)) 
KX(2,4)=H*X2(XN(1,I)+KX(1,3) ,XN(2,I)+KX(2,3) ,XN(4,I)+ 
!KX(4,3) ,U1(I+1)) 
KX(3,4)=H*X3(XN(2,I)+KX(2,3) ,XN(3,I)+KX(3,3)) 
KX(4,4)=H*X4(XN(1,I)+KX(1,3) ,XN(3,I)+KX(3,3) ,XN(4,I)+ 
!KX(4,3) ,U2(I+l)) 
~c Walk the T,T*,T**, and the V eqns here!!! 
XN(l,I+l)=XN(1,I)+(KX(1,1)+2*KX(1,2)+2*KX(1,3)+KX(1,4) )/6. 
XN(2,I+1)=XN(2,I)+(KX(2,1)+2*KX(2,2)+2*KX(2,3)+KX(2,4))16. 
XN(3,I+1)=XN(3,I)+(KX(3,1)+2*KX(3,2)+2*KX(3,3)+KX(3,4))16. 
XN(4,I+1)=XN(4,I)+(KX(4,l)+2*KX(4,2)+2*KX(4,3)+KX(4,4) )/6. 
123 END DO 
C Now work from final time to initial time! 
<W' C Given the guess on Y's, we got the X's, 
~C now we have to work 
C backwards to see if it's correct! The next small loop is to initialize 
<W'C the X() values for the first time through only 
IF (Z.EQ.2) THEN 
DO P=1,4 
DO I=1,M 
X(P,I)=XN(P,I) 
END DO 
END DO 
Z=O 
ELSE 
END IF 
~ C Next work backwards .. 
DO P=1,4 
YN(P,M)=FCY 
END DO 
~C NOW we must walk the 4 adjoints (JUST the Y eqns!) 
~ 
.... 
WI" 
,., 
... 
.... 
.,. 
... 
... 
.,. 
... 
... 
... 
WI" 
.... 
.., 
.... 
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., 
~ 
.... 
.... 
.... 
.,. 
.,. 
... 
., 
.., 
.., 
.... 
., 
.., 
WI" 
DO I=1,N 
K=2+N-I 
KY(1,1)=H*Z1(YN(1,K) ,YN(2,K) ,YN(4,K) ,XN(1,K),XN(2,K) ,XN(3,K), 
!XN(4,K) ,U1 (K)) 
KY(2,1)=H*Z2(YN(1,K),YN(2,K) ,YN(3,K) ,XN(1,K)) 
KY(3,1)=H*Z3(YN(1,K),YN(3,K) ,YN(4,K) ,U2(K)) 
KY(4,1)=H*Z4(YN(1,K) ,YN(2,K) ,YN(4,K) ,XN(1,K),XN(4,K) ,U1(K) 
KY(1,2)=H*Z1(YN(1,K)-KY(1,1)/2,YN(2,K)-KY(2,1)/2,YN(4, K)-
!KY(4,1)/2, (XN(1,K-1)+XN(1,K))/2, (XN(2,K-1)+XN(2,K))/2, (XN(3,K-1)+ 
!XN(3,K))/2, (XN(4,K-1)+XN(4,K) )/2, (U1(K-1)+U1(K))/2) 
KY(2,2)=H*Z2(YN(1,K)-KY(1,1)/2,YN(2,K)-KY(2,1)/2,YN(3, K) 
!KY(3,1)/2, (XN(1,K-1)+XN(1,K))/2) 
KY(3,2)=H*Z3(YN(1,K)-KY(1,1)/2,YN(3,K)-KY(3,1)/2,YN(4, K)-
! KY (4 , 1) 12, (U2 (K-1) +U2 (K) ) 12) 
KY(4,2)=H*Z4(YN(1,K)-KY(1,1)/2,YN(2,K)-KY(2,1)/2,YN(4, K)-
! KY ( 4 , 1) 1 2, (XN ( 1 , K -1 ) + XN ( 1, K) ) 1 2, (XN ( 4 , K -1 ) + XN ( 4 , K) ) 1 2, (U 1 (K -1 ) + 
! U1 (K) ) 12) 
KY(1,3)=H*Z1(YN(1,K)-KY(1,2)/2,YN(2,K)-KY(2,2)/2,YN(4,K ) 
!KY(4,2)/2, (XN(1,K-1)+XN(1,K))/2, (XN(2,K-1)+XN(2,K))/2, (XN(3,K-1)+ 
!XN(3,K) )/2, (XN(4,K-1)+XN(4,K))/2, (U1(K-1)+U1(K))/2) 
KY(2,3)=H*Z2(YN(1,K)-KY(1,2)/2,YN(2,K)-KY(2,2)/2,YN(3, K)-
! KY ( 3 , 2) 1 2, (XN ( 1 , K -1 ) + XN ( 1 , K) ) 1 2 ) 
KY(3,3)=H*Z3(YN(1,K)-KY(1,2)/2,YN(3,K)-KY(3,2)/2,YN(4, K) 
! KY ( 4 , 2 ) 12, (U2 (K -1 ) + U2 (K) ) 12 ) 
KY(4,3)=H*Z4(YN(1,K)-KY(1,2)/2,YN(2,K)-KY(2,2)/2,YN(4, K)-
!KY(4,2)/2, (XN(1,K-1)+XN(1,K))/2, (XN(4,K-1)+XN(4,K))/2, (U1(K-1)+ 
! U1 (K) ) 12) 
KY(1,4)=H*Z1(YN(1,K)-KY(1,3) ,YN(2,K)-KY(2,3) ,YN(4,K)-
!KY(4,3) ,XN(1,K-1) ,XN(2,K-1) ,XN(3,K-1) ,XN(4,K-1) ,U1(K-1)) 
KY(2,4)=H*Z2(YN(1,K)-KY(1,3) ,YN(2,K)-KY(2,3) ,YN(3,K) 
!KY(3,3) ,XN(1,K-1)) 
KY(3,4)=H*Z3(YN(1,K)-KY(1,3) ,YN(3,K)-KY(3,3) ,YN(4,K) 
! KY ( 4 , 3) , U 2 (K -1) ) 
KY(4,4)=H*Z4(YN(1,K)-KY(1,3) ,YN(2,K)-KY(2,3) ,YN(4,K)-
!KY(4,3) ,XN(1,K-1) ,XN(4,K-1) ,U1(K-1») 
YN(1,K-1)=YN(1,K)-(KY(1,1)+2*KY(1,2)+2*KY(1,3)+KY(1,4) )/6 . 
YN(2,K-1)=YN(2,K) (KY(2,1)+2*KY(2,2)+2*KY(2,3)+KY(2,4))/6 . 
YN ( 3 , K -1 ) = YN ( 3 , K) ( KY ( 3 I 1 ) + 2 * KY ( 3 , 2 ) + 2 * KY ( 3 , 3 ) + KY (3 , 4) ) 1 6 . 
YN(4,K-1)=YN(4,K) (KY(4,1)+2*KY(4,2)+2*KY(4,3)+KY(4,4) )/6 . 
END DO 
C Now the test for convergence ... 
SUM 0.0 
DO P=1,4 
DO I=l,M 
SUM=SUM+ABS(YN(P,I)-Y(P,I) )+ABS(XN(P,I)-X(P,I)) 
END DO 
END DO 
IF (SUM.GT.EPSI) THEN 
DO P=l,4 
DO I=l,M 
Y(P,I)=YN(P,I) 
X(P,I)=XN(P,I) 
END DO 
END DO 
COUNTER=COUNTER+l 
IF(COUNTER.GE.IOOO) THEN 
PRINT*, 'NO convergence!!' 
STOP 
ELSE 
GO TO 57 
END IF 
ELSE 
END IF 
DO I=l,M 
PRINT*, H*(I-l) ,XN(l,I) ,XN(4,I),Ul(I) ,U2(I) 
END DO 
PRINT*, XN(2,lOl) ,XN(3,lOl) 
END 
6 Table of ParaII).eters 
Bl = 50 mm -3, B2 400 mm -3 balancing constants 
s 10 days-lmm-3 , a linear growth rate constant 
/-LT .02 days-I, a death rate constant for both healthy and la-
tently infected T cells 
r = .03 days-I, a logistic growth rate constant 
Tmax = 1500 mm-3 , the maximum number of T cells (healthy and 
infected) per mm3 
kl = 2.4 X 10-5 mm3days-l, a rate constant for the infective in-
teraction of viral particles and T cells 
k2 .003 days-I, a rate constant describing the transfer of T cells 
from the latently infected state T* to an actively infected state T** 
/-Lb = .24 days-I, a death rate constant for actively infected T cells, 
or equivalently a birthing rate for the HIV virus 
N 1200, the number of viral particles produced per dying T cell 
/-Lv = 2.4 days-I, a death rate constant for the HIV virus 
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